Amaethon Limited, the UK based intellectual property business, announces that ArborGen LLC, the US based forestry biotechnology company, has signed a non-exclusive research licence and option agreement covering a group of proprietary genes discovered within the Centre for Novel Agricultural Products (CNAP) the world class gene discovery research centre based in the University of York, England. The financial terms of the agreement were not disclosed.

Dr Graham P. Howe, CEO of Amaethon, stated “ As a world leader, ArborGen is an ideal partner and collaborator to take the current genes forward and to assist in the discovery of new targets. This agreement further demonstrates the high quality and commercial relevance of the research undertaken within our partner CNAP.”

Professor Dianna Bowles, Director of CNAP, said “We are delighted to enter a new partnership with ArborGen and gain the opportunity of taking our scientific discoveries into application”

Dr. Maud A. Hinchee, Chief Technology Officer at ArborGen commented “CNAP is a first-class research centre, and ArborGen is pleased to be able to apply their research discoveries towards improving plantation trees grown for the forestry industry.”

About Amaethon Limited

Amaethon was established in 2003 as an innovative partnership between the University of York and IP2IPO Group plc and created to commercialise the research of CNAP, the flagship plant and microbial gene discovery research centre based in the University of York.

IP2IPO, the Alternative Investment Market listed intellectual property business, invested £1.15m receiving a one third equity stake. The University of York granted Amaethon exclusive rights over CNAP’s research for 25 years in exchange for a two-thirds equity position. In addition, IP2IPO has also committed to make seed capital investments in spin-out companies created by Amaethon based upon CNAP research.

Amaethon operates as an entirely stand-alone business securing licenses, identifying and creating new companies, and capturing and managing industry sponsored research contracts from offices based in the Biosciences Building on the York Science Park, England.

Amaethon’s objective is to become a world leading technology commercialisation company in the field of gene discovery research targeted and the utilisation of plants and microbes as cell factories.

About ArborGen LLC

ArborGen LLC, formed in 2000, is committed to improving trees and forestry through genetic research and biotechnology. It is a joint venture partnership of biotech researchers and plant scientist from a number of research based institutions in the United States and New Zealand. This combination of talents, expertise, infrastructure and diversity of patented genetic materials has created a dynamic and versatile team of more than 90 scientists and technicians who are advancing the science of forest genetics.

ArborGen specializes in developing and commercializing technology, products and services that provide environmental and productivity benefits for the forest industry. The focus of ArborGen's research program is on commercially important plantation tree species that are planted world-wide.

Turning plant genes into corporate cash

By Patricia Short
Chemical & Engineering News via Checkbiotech.org

Amaethon aims to transfer university research in botany into money-spinning deals with outside industry.

Amaethon—pronounced a-MY-e-thon—is a god of agriculture in Celtic mythology. It’s also the name of a new technology-transfer company, formed last November by the University of York, in England, and venture-capitalists IP2IPO.

Amaethon was established as a stand-alone firm to commercialize the research of the Centre for Novel Agricultural Products (CNAP), a part of the University of York biology department devoted to plant genetics.

The university owns two-thirds of Amaethon and has granted the firm 25-year exclusive rights to CNAP’s research. IP2IPO holds the remaining third, following a $2 million investment; the venture-capital firm has also committed roughly $1.4 million to spin-off companies based on CNAP research.

U.K.-based IP2IPO focuses on moving university-generated intellectual property into the commercial sphere. For example, last month, it launched in an initial public offering of Offshore Hydrocarbon Mapping, an offshoot of the U.K’s University of Southampton that finds underwater oil and gas.

The hookup with the University of York was the culmination of work by Graham P. Howe in his position as commercial director of CNAP. Howe—whose background prior to joining CNAP in 2002 includes stints at ICI, Chirotech (now part of Dow Chemical), and Clariant’s Life Science Molecules unit—is now chief executive officer of Amaethon.

In existence only six months, Amaethon—which has a full-time staff of four—already has several commercial contracts under its corporate belt.

Earlier this month, Amaethon signed a nonexclusive research agreement in forestry biotechnology with ArborGen, Summerville, S.C., based on a group of genes discovered at CNAP. ArborGen itself is a partnership of biotech researchers and plant scientists from a number of research-based institutions in the U.S. and New Zealand.

As Maud A. Hinchee, chief technology officer at ArborGen, puts it, “ArborGen is pleased to be able to apply [CNAP’s] research discoveries toward improving plantation trees grown for the forestry industry.”

And in March, Amaethon agreed to collaborate with Oxford Chemicals Ltd. in flavor and fragrance chemicals. Under the agreement, Oxford Chemicals—part of U.K. specialty chemicals company Yule Catto—will cofund a proof-of-principle research project, to be conducted by CNAP, aimed at creating new enzyme-based routes to aroma chemicals (C&EN, March 29, page 12).

The collaboration will apply biocatalysts derived from proprietary CNAP genes to the synthesis of aroma chemicals identified by Oxford Chemicals. Oxford will have exclusive rights in the area of flavors and fragrances; Amaethon will retain the right to use the research in all other applications.

At the company’s official launch last month, Howe noted that Amaethon has four main functions: developing projects, offering research services, licensing, and coordinating spin-off companies.

It seeks industry-funded research projects at CNAP, particularly in analytical glycobiology—glycoproteins, polysaccharides, and other glycoconjugates. Such industry funding, in turn, helps support the research chairs at CNAP.

A variety of technologies fill Amaethon’s licensing quiver. Its work in polyunsaturated fatty acids biosynthesis, for example, exploits the genes encoding enzymes responsible for synthesis of these compounds. Another licensing project involves a nucleic acid molecule in the spider Euprosthenops spidroin. The molecule encodes a protein present in the spider’s major dragline silk, which shows, according to Amaetheon, better strength, elasticity, and resistance to solvents than most dragline silks from other species.

All of the company’s work focuses on what Howe calls the “microbial cell factories” within plants. Products of these factories can include fuels, plastics and bioplastics, fine chemicals, pharmaceutical active ingredients, food additives, cosmetic ingredients, vitamins, colorants, and aroma components. They all contribute to what he sees as a market with considerable growth potential.

For example, the global market for transgenic crops reached $3 billion in 2002 and is expected to hit $25 billion by 2010.

Amaethon is also keen to encourage strategic partnerships, Howe says. For example, CNAP has established a phytochemistry partnership, the Noble Laboratory, with the Plant Biology Division of the Samuel Roberts Noble Foundation in Ardmore, Okla. The foundation is providing slightly more than $2 million in funding for the laboratory, located at CNAP. Richard A. Dixon, a professor at the Noble Foundation (in Ardmore), is CNAP’s chair of phytochemical genomics and codirector of the laboratory with professor Pierre Broun, who is CNAP’s chair of metabolic engineering.

In U.K. academia, argues David Norwood, CEO of IP2IPO, “most people who possess the deep intellectual property—the great ideas—are hopeless at selling themselves to us, the venture capitalists and merchant bankers. Others have been very good at ‘selling’—they have raised millions and lost it all doing silly things. It has given genuine academics a bad name.

“IP2IPO wants to help its partners lead the way,” he says, “to create value by exploiting ideas.”

Copyright © 2004